CLEC12A and acute myeloid leukemia: For instance, Wang et al. 81 developed tandem CAR-T cells targeting CLL-1 and CD123 to assess their therapeutic potential in AML in vitro, and they found that these dual-targeting CAR-T cells exhibited robust killing effects and released a large number of cytokines, demonstrating a significant ability to kill single antigens and multi-target tumour cells.